CoChat
Cited by 585

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident: CDC Recommendations

Prepared by, Bower, William A., Hendricks, Katherine, Pillai, Satish, Guarnizo, Julie, Meaney-Delman, Dana · 2015 · MMWR. Recommendations and Reports

Abstract

In 2014, CDC published updated guidelines for the prevention and treatment of anthrax (Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014;20[2]. Available at http://wwwnc.cdc.gov/eid/article/20/2/13-0687_article.htm). These guidelines provided recommended best practices for the diagnosis and treatment of persons with naturally occurring or bioterrorism-related anthrax in conventional medical settings. An aerosolized release of Bacillus anthracis spores over densely populated areas could become a mass-casualty incident. To prepare for this possibility, the U.S. government has stockpiled equipment and therapeutics (known as medical countermeasures [MCMs]) for anthrax prevention and treatment. However, previously developed, publicly available clinical recommendations have not addressed the use of MCMs or clinical management during an anthrax mass-casualty incident, when the number of patients is likely to exceed the ability of the health care infrastructure to provide conventional standards of care and supplies of MCMs might be inadequate to meet the demand required. To address this gap, in 2013, CDC conducted a series of systematic reviews of the scientific literature on anthrax to identify evidence that could help clinicians and public health authorities set guidelines for intravenous antimicrobial and antitoxin use, diagnosis of anthrax meningitis, and management of common anthrax-specific complications in the setting of a mass-casualty incident. Evidence from these reviews was presented to professionals with expertise in anthrax, critical care, and disaster medicine during a series of workgroup meetings that were held from August 2013 through March 2014. In March 2014, a meeting was held at which 102 subject matter experts discussed the evidence and adapted the existing best practices guidance to a clinical use framework for the judicious, efficient, and rational use of stockpiled MCMs for the treatment of anthrax during a mass-casualty incident, which is described in this report. This report addresses elements of hospital-based acute care, specifically antitoxins and intravenous antimicrobial use, and the diagnosis and management of common anthrax-specific complications during a mass-casualty incident. The recommendations in this report should be implemented only after predefined triggers have been met for shifting from conventional to contingency or crisis standards of care, such as when the magnitude of cases might lead to impending shortages of intravenous antimicrobials, antitoxins, critical care resources (e.g., chest tubes and chest drainage systems), or diagnostic capability. This guidance does not address primary triage decisions, anthrax postexposure prophylaxis, hospital bed or workforce surge capacity, or the logistics of dispensing MCMs. Clinicians, hospital administrators, state and local health officials, and planners can use these recommendations to assist in the development of crisis protocols that will ensure national preparedness for an anthrax mass-casualty incident.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.rr6404a1

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 47

  1. MacIntyre, 2006, Development of a risk-priority score for category A bioterrorism agents as an aid for public health policy., Mil Med, 171, 589, 10.7205/MILMED.171.7.589 · doi:10.7205/milmed.171.7.589
  2. Franz, 2009, Preparedness for an anthrax attack., Mol Aspects Med, 30, 503, 10.1016/j.mam.2009.07.002 · doi:10.1016/j.mam.2009.07.002
  3. Fernelius, 1960, Comparison of graded and quantal virulence tests for Bacillus Anthracis Spores., J Bacteriol, 79, 594, 10.1128/JB.79.4.594-600.1960 · doi:10.1128/jb.79.4.594-600.1960
  4. Hanna, 1999, Understanding Bacillus anthracis pathogenesis., Trends Microbiol, 7, 180, 10.1016/S0966-842X(99)01507-3 · doi:10.1016/s0966-842x(99)01507-3
  5. Fish, 1968, Purification and properties of in vitro-produced anthrax toxin components., J Bacteriol, 95, 907, 10.1128/JB.95.3.907-918.1968 · doi:10.1128/jb.95.3.907-918.1968
  6. Kyriacou, 2004, Clinical predictors of bioterrorism-related inhalational anthrax., Lancet, 364, 449, 10.1016/S0140-6736(04)16769-X · doi:10.1016/s0140-6736(04)16769-x
  7. Walsh, 2007, A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor., Clin Infect Dis, 44, 968, 10.1086/512372 · doi:10.1086/512372
  8. Sprenkle, 2014, Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA., Emerg Infect Dis, 20, 310, 10.3201/eid2002.130245 · doi:10.3201/eid2002.130245
  9. Sirisanthana, 2002, Anthrax of the gastrointestinal tract., Emerg Infect Dis, 8, 649, 10.3201/eid0807.020062 · doi:10.3201/eid0807.020062
  10. Beatty, 2003, Gastrointestinal anthrax: review of the literature., Arch Intern Med, 163, 2527, 10.1001/archinte.163.20.2527 · doi:10.1001/archinte.163.20.2527
  11. Demirdag, 2003, Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey., Infection, 31, 327, 10.1007/s15010-003-3169-3 · doi:10.1007/s15010-003-3169-3
  12. Doust, 1968, Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax)., Dis Chest, 53, 773, 10.1378/chest.53.6.773 · doi:10.1378/chest.53.6.773
  13. Davies, 1985, A major epidemic of anthrax in Zimbabwe: the experience at the Beatrice Road Infectious Diseases Hospital, Harare., Cent Afr J Med, 31, 176
  14. Lanska, 2002, Anthrax meningoencephalitis., Neurology, 59, 327, 10.1212/WNL.59.3.327 · doi:10.1212/wnl.59.3.327
  15. Institute of Medicine. Finding what works in health care: standards for systematic reviews. Eden J, Levit L, Berg A, Morton S, eds: The National Academies Press; 2011.
  16. Hendricks KA, Wright ME, Shadomy SV, Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014;20. Available at .10.3201/eid2002.130687 · doi:10.3201/eid2002.130687
  17. Huang, Antitoxin treatment for inhalation anthrax: a systematic review., Health Security.
  18. Pillai, antimicrobial treatment for systemic anthrax: analysis of cases from 1945–2014 identified through systematic literature review., Health Security.
  19. Patel, 2012, Clozapine-induced peripheral and pleural fluid eosinophilia., Ann Pharmacother, 46, e4, 10.1345/aph.1Q642 · doi:10.1345/aph.1q642
  20. Roy, 2007, Does this patient with a pericardial effusion have cardiac tamponade?, JAMA, 297, 1810, 10.1001/jama.297.16.1810 · doi:10.1001/jama.297.16.1810
  21. Azam, 2011, Treatment of pericardial disease., Cardiovasc Ther, 29, 308, 10.1111/j.1755-5922.2010.00151.x · DOI
  22. Loukas, 2012, Pericardiocentesis: a clinical anatomy review., Clin Anat, 25, 872, 10.1002/ca.22032 · doi:10.1002/ca.22032
  23. McGibbon, 2007, An evidence-based manual for abdominal paracentesis., Dig Dis Sci, 52, 3307, 10.1007/s10620-007-9805-5 · doi:10.1007/s10620-007-9805-5
  24. Bradley, 2014, Pediatric anthrax clinical management., Pediatrics, 133, e1411, 10.1542/peds.2014-0563 · doi:10.1542/peds.2014-0563
  25. Institute of Medicine. Crisis standards of care: a systems framework for catastrophic disaster response. Washington, DC: The National Academies Press; 2012.
  26. Dries, 2014, Special populations: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement., Chest, 146, e75S, 10.1378/chest.14-0737 · doi:10.1378/chest.14-0737
  27. Tabatabaie, 1993, Bacillus anthracis as a cause of bacterial meningitis., Pediatr Infect Dis J, 12, 1035, 10.1097/00006454-199312000-00020 · doi:10.1097/00006454-199312000-00020
  28. Berger T, Kassirer M, Aran AA. Injectional anthrax: new presentation of an old disease. Euro Surveill. 2014;19(32):pii=20877. Available at .DOI: 10.2807/1560-7917.ES2014.19.32.20877 · DOI
  29. Holty, 2006, Anthrax: a systematic review of atypical presentations., Ann Emerg Med, 48, 200, 10.1016/j.annemergmed.2005.11.035 · DOI
  30. Lincoln, 1964, Haines B. anthrax., Adv Vet Sci, 9, 327
  31. Yee, 2010, Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment., Comp Med, 60, 461
  32. Anaraki, 2008, Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008., Euro Surveill, 13, 19076., 10.2807/ese.13.51.19076-en · doi:10.2807/ese.13.51.19076-en
  33. Klempner, 2010, Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock., N Engl J Med, 363, 766, 10.1056/NEJMcpc1003887 · doi:10.1056/nejmcpc1003887
  34. Rubinson, 2010, MSOFA: An important step forward, but are we spending too much time on the SOFA?, Disaster Med Public Health Prep, 4, 270, 10.1001/dmp.2010.41 · doi:10.1001/dmp.2010.41
  35. Booth, 2014, Confirmed Bacillus anthracis infection among persons who inject drugs, Scotland, 2009-2010., Emerg Infect Dis, 20, 1452, 10.3201/eid2009.131481 · doi:10.3201/eid2009.131481
  36. Tabatabaie, 1993, Bacillus anthracis as a cause of bacterial meningitis., Pediatr Infect Dis J, 12, 1035, 10.1097/00006454-199312000-00020 · doi:10.1097/00006454-199312000-00020
  37. Russell, 2013, Two anthrax cases with soft tissue infection, severe oedema and sepsis in Danish heroin users., BMC Infect Dis, 13, 408, 10.1186/1471-2334-13-408 · doi:10.1186/1471-2334-13-408
  38. Iserson, 2003, Ethical resource distribution after biological, chemical, or radiological terrorism., Camb Q Healthc Ethics, 12, 455, 10.1017/S0963180103124164 · doi:10.1017/s0963180103124164
  39. Meaney-Delman, 2012, Anthrax cases in pregnant and postpartum women: a systematic review., Obstet Gynecol, 120, 1439, 10.1097/AOG.0b013e318270ec08 · DOI
  40. Place, 2007, Bioterrorism-related inhalational anthrax: can extrapolated adult guidelines be applied to a pediatric population?, Biosecur Bioterror, 5, 35, 10.1089/bsp.2006.0011 · doi:10.1089/bsp.2006.0011
  41. Bravata, 2007, Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005., Arch Pediatr Adolesc Med, 161, 896, 10.1001/archpedi.161.9.896 · doi:10.1001/archpedi.161.9.896
  42. Barr JR, Boyer AE, Hoffmaster AR, Detection and quantification of anthrax toxins by mass spectrometry: application to clinical anthrax [Abstract 77-Mo:160]. International Conference onBacillus anthracis, B cereusandB thuringiensis; August 7–11, 2011; Bruges, Belgium.
  43. Boyer, 2007, Detection and quantification of anthrax lethal factor in serum by mass spectrometry., Anal Chem, 79, 8463, 10.1021/ac701741s · doi:10.1021/ac701741s
  44. Boyer, 2011, Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax., J Infect Dis, 204, 1321, 10.1093/infdis/jir543 · doi:10.1093/infdis/jir543
  45. Boyer AE, Lins RC, Gallegos M, Kinetics of anthrax toxins, lethal factor and edema factor during inhalation anthrax in rhesus macaques [Abstract 77-Mo:160]. International Conference onBacillus anthracis, B cereusandB thuringiensis; August 7–11, 2011; Bruges, Belgium.
  46. Boyer AE, Gallegos-Candela M, Lins RC, Relationship between circulating lethal factor, edema factor and toxin complexes during clinical and experimental anthrax [Abstract S8:5:44]. International Conference onBacillus anthracis, B cereusandB thuringiensis; September 1–5, 2013, Victoria, British Columbia, Canada.
  47. Kammanadiminti, 2014, Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax., PLoS One, 9, e106393, 10.1371/journal.pone.0106393 · doi:10.1371/journal.pone.0106393

Cited by

See all 585

Metadata

Authors
by, P., Bower, W. A., Hendricks, K., Pillai, S., Guarnizo, J., & Meaney-Delman, D.
Venue
MMWR. Recommendations and Reports
Published
2015-12-04
Volume
64
Issue
4
Pages
1-22
ISSN
  • 1057-5987 (ISSN-L)
  • 1545-8601
OpenAlex
W2416229675
Cited by
585
References
36
FWCI
34.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.